Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

U.S. startups get OK for smartphone-based heart tracking

Published 29/08/2014, 00:27
U.S. startups get OK for smartphone-based heart tracking

By Christina Farr

SAN FRANCISCO (Reuters) - For a growing U.S. ageing population, tracking heart health via a smartphone can mean the difference between life and death.

This week, two Silicon Valley startups received a green-light from the U.S. Food and Drug Administration for mobile applications that monitor patients from home, a step forward for a nascent digital health industry that has pressed for more clarity from the agency on regulations.

AliveCor said it received the FDA's approval to detect serious heart conditions in electrocardiogram (ECG) readings taken from a mobile device. The company says its newly-approved algorithm can detect atrial fibrillation, a form of cardiac arrhythmia that affects about one in four adults over the age of 40.

If its smartphone-compatible heart-monitor device detects an abnormality, a physician could intervene before the patient experiences a stroke or other life-threatening event.

The device fits most smartphones and rests on a patient's finger or chest to record an ECG.

"Atrial fibrillation is very hard to identify," said Euan Thomson, AliveCor's chief executive. "A large group of people have it, but don't know they have it."

Thomson said AliveCor can detect the condition and send the data to a cardiologist for review. The company plans to incorporate this algorithm into its application and make it available to consumers by September.

In addition, startup Vital Connect received approval for a patch -- the "HealthPatch MD" -- that patients can attach to one of three areas on their chest and view their own biometric data on a mobile device.

Sensors embedded in the band-aid sized patch track heart rate, pulse variability, respiratory rate, skin temperature, steps, "fall" detection and more.

Valeska Schroeder, the company's vice president of product management, said the medical device will hit the market in the United States, and potentially also Canada and Europe, by the end of the year. Patients need a prescription to buy the device.

What is unique about Vital Connect is that it puts the data in context, Schroeder explained. If a patient's heart rate spikes when they are lying flat in bed, that is typically a worrisome sign. But during exercise or a fall, it is a typical occurrence. If they opt in, physicians get notified when their patients hit or exceed set thresholds.

Vital Connect first hit the headlines when Apple poached one of its senior executives, Ravi Narasimhan, as part of a larger effort to hire talent from the medical field.

"We know we are working in a hot market," said Schroeder. "We know other firms are interested in making related products."

These companies are taking different approaches, but they share the goal of helping doctors track patients remotely and take steps to prevent fatal outcomes. Data may also inform physicians about whether their patients should schedule an in-person or emergency room visit.

According to the Centers for Disease Control, 129.8 million people visited the emergency room in 2010 and 13 percent of these visits resulted in hospital readmission.

"By getting an intelligent device in the hands of a patient, we hope to fulfil the vision for mobile health," said Thomson.

(Reporting By Christina Farr; editing by Andrew Hay)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.